Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity.
Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity.
复制标题
DOI：
10.3389/fendo.2021.735019
复制
发表时间：
2021
影响因子：
5.2
通讯作者：
Tan TMM
中科院分区：
文献类型：
--
作者：
Hope DCD;Vincent ML;Tan TMM
肥胖和2型糖尿病代表了全球健康挑战，并且对持久和有效的药物治疗的需求尚未得到满足。尽管长效胰高血糖素样肽-1（GLP-1）类似物目前已常规用于糖尿病，并且目前正在用于肥胖症本身，但对更好治疗的需求推动了共激动剂的开发，其理论优势是通过靶向多个途径提高疗效并减少不良反应。在这篇综述中，我们强调了过去和现在的进展，我们的理解和发展的基础上GLP-1/胰高血糖素共激动剂的治疗。我们还反映了在临床前和人体临床试验结果的背景下，改变GLP-1：胰高血糖素活性和比例的不同影响。特别是，胰高血糖素的多种代谢作用突出了理解个体激素作用的重要性，以告知GLP-1/胰高血糖素共激动剂的安全、有效和定制使用，以在未来靶向体重减轻和代谢疾病。
Obesity and Type 2 diabetes represent global health challenges, and there is an unmet need for long-lasting and effective pharmacotherapies. Although long-acting glucagon-like peptide-1 (GLP-1) analogues are now in routine use for diabetes and are now being utilised for obesity per se, the need for ever better treatments has driven the development of co-agonists, with the theoretical advantages of improved efficacy by targeting multiple pathways and reduced adverse effects. In this review, we highlight the past and present progress in our understanding and development of treatments based on GLP-1/glucagon co-agonism. We also reflect on the divergent effects of varying the GLP-1:glucagon activity and ratio in the context of pre-clinical and human clinical trial findings. In particular, the multiple metabolic actions of glucagon highlight the importance of understanding the contributions of individual hormone action to inform the safe, effective and tailored use of GLP-1/glucagon co-agonists to target weight loss and metabolic disease in the future.
登录
查看更多内容
影响因子：
3
作者：
BATAILLE, D;JARROUSSE, C;DUBRASQUET, M
通讯作者：
DUBRASQUET, M
影响因子：
4.8
作者：
Dakin, CL;Small, CJ;Bloom, SR
通讯作者：
Bloom, SR
影响因子：
4.8
作者：
Dakin, CL;Gunn, I;Bloom, SR
通讯作者：
Bloom, SR
影响因子：
4.8
作者：
Druce, Maralyn R.;Minnion, James S.;Bloom, Stephen R.
通讯作者：
Bloom, Stephen R.
影响因子：
5.8
作者：
Cohen, MA;Ellis, SM;Bloom, SR
通讯作者：
Bloom, SR